News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
13,417 Results
Type
Article (1667)
Company Profile (13)
Press Release (11737)
Section
Business (3802)
Career Advice (25)
Deals (458)
Drug Delivery (5)
Drug Development (2489)
Employer Resources (6)
FDA (417)
Job Trends (748)
News (6227)
Policy (844)
Tag
2027 Genetown Standard (1)
Academia (108)
Accelerated approval (3)
Adcomms (5)
Allergies (2)
Alliances (822)
ALS (13)
Alzheimer's disease (47)
Antibody-drug conjugate (ADC) (20)
Approvals (374)
Artificial intelligence (23)
ASCO (30)
Autoimmune disease (11)
Automation (1)
Bankruptcy (5)
Best Places to Work (698)
BIO (2)
Biosimilars (1)
Biotechnology (12)
Bladder cancer (5)
Brain cancer (8)
Breast cancer (55)
Cancer (273)
Cardiovascular disease (8)
Career advice (18)
CAR-T (17)
CDC (21)
Cell therapy (57)
Clinical research (1636)
Collaboration (70)
Compensation (68)
Complete response letters (6)
COVID-19 (840)
CRISPR (2)
C-suite (51)
Cystic fibrosis (7)
Data (342)
Depression (4)
Diabetes (8)
Diagnostics (174)
Digital health (1)
Diversity, equity & inclusion (2)
Drug discovery (8)
Drug pricing (3)
Duchenne muscular dystrophy (27)
Earnings (1273)
Editorial (17)
Employer branding (1)
Employer resources (5)
Events (2808)
Executive appointments (43)
FDA (525)
Friedreich's ataxia (1)
Frontotemporal dementia (7)
Funding (55)
Gene editing (10)
Generative AI (4)
Gene therapy (34)
GLP-1 (34)
Government (392)
Guidances (8)
Healthcare (561)
Hematology (9)
Huntington's disease (2)
IgA nephropathy (4)
Immunology and inflammation (10)
Immuno-oncology (1)
Indications (3)
Infectious disease (887)
Inflammatory bowel disease (7)
Influenza (27)
Intellectual property (11)
Interviews (1)
IPO (224)
IRA (1)
Job creations (62)
Job search strategy (17)
JPM (3)
Kidney cancer (2)
Labor market (10)
Layoffs (28)
Leadership (1)
Legal (109)
Liver cancer (1)
Lung cancer (22)
Lymphoma (9)
Machine learning (3)
Manufacturing (42)
MASH (3)
Medical device (272)
Medtech (292)
Mergers & acquisitions (274)
Metabolic disorders (40)
mRNA (135)
Multiple sclerosis (8)
Neurodegenerative disease (12)
Neuropsychiatric disorders (1)
Neuroscience (99)
NextGen: Class of 2026 (183)
Non-profit (116)
Now hiring (29)
Obesity (21)
Opinion (12)
Ovarian cancer (4)
Pain (18)
Pancreatic cancer (26)
Parkinson's disease (7)
Patents (33)
Patient recruitment (35)
People (1370)
Phase 1 (732)
Phase 2 (755)
Phase 3 (563)
Pipeline (365)
Policy (29)
Postmarket research (37)
Preclinical (308)
Prostate cancer (12)
Psychedelics (7)
Radiopharmaceuticals (32)
Rare diseases (82)
Real estate (133)
Recruiting (3)
Regulatory (648)
Research institute (109)
Resumes & cover letters (4)
Rett syndrome (1)
RNA editing (1)
RSV (24)
Series A (8)
Series B (5)
Service/supplier (1)
Sickle cell disease (16)
Special edition (1)
Sponsored (2)
Startups (96)
Supply chain (2)
Tariffs (4)
The Weekly (22)
Vaccines (401)
Venture capital (7)
Weight loss (11)
Women's health (6)
Date
Last 7 days (24)
Last 30 days (80)
Last 365 days (1074)
2026 (653)
2025 (1046)
2024 (1208)
2023 (1201)
2022 (1407)
2021 (1674)
2020 (1263)
2019 (771)
2018 (575)
2017 (438)
2016 (433)
2015 (449)
2014 (332)
2013 (251)
2012 (277)
2011 (289)
2010 (261)
Location
Africa (33)
Alabama (4)
Arizona (1)
Arkansas (1)
Asia (425)
Australia (199)
California (336)
Canada (43)
China (22)
Colorado (6)
Connecticut (26)
Delaware (4)
Europe (1427)
Florida (80)
Georgia (3)
Idaho (1)
Illinois (53)
Indiana (38)
Iowa (1)
Japan (9)
Kentucky (2)
Maryland (26)
Massachusetts (572)
Michigan (1)
Minnesota (3)
Missouri (1)
New Hampshire (2)
New Jersey (63)
New York (76)
North Carolina (71)
North Dakota (1)
Northern California (142)
Ohio (7)
Pennsylvania (74)
Puerto Rico (1)
Rhode Island (2)
South America (21)
Southern California (159)
Tennessee (2)
Texas (505)
United States (1889)
Utah (6)
Virginia (2)
Washington D.C. (5)
Washington State (15)
Wisconsin (1)
13,417 Results for "moderna_tx".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Personalis Reports Second Quarter 2026 Results and Recent Highlights
August 4, 2026
·
11 min read
Press Releases
Personalis Reports First Quarter Results and Recent Highlights
May 8, 2026
·
10 min read
FDA
FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants
August 22, 2024
·
5 min read
Press Releases
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights
January 8, 2026
·
8 min read
Approvals
Moderna’s flu shot crosses FDA finish line, bouncing back from regulatory roadblock
The FDA in February slapped Moderna’s vaccine with a refusal-to-file letter—though the agency backtracked a few days later and accepted a revised submission for review. An advisory committee in June unanimously backed mFLUVISA’s approval.
August 6, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
February 27, 2026
·
11 min read
Press Releases
Messenger RNA Market Research Report 2025-2035, Competitive Analysis of Pfizer, GSK, Arcturus Therapeutics, AstraZeneca, Beam Therapeutics, Moderna, Oncotelic, SK Bioscience, Sangamo, Sanofi CureVac
June 11, 2025
·
6 min read
Earnings
Moderna maintains 10% growth target despite Phase 3 norovirus miss
Moderna’s norovirus vaccine failed in a Phase 3 trial, but the company still has faith in an ambitious revenue growth target thanks to ex-U.S. vaccine sales and a unanimous FDA adcomm win for mFLUSIVA.
July 31, 2026
·
4 min read
·
Gabrielle Masson
Adcomms
Moderna’s mRNA flu shot wins unanimous support at FDA adcomm in rebuke of former leadership
The FDA in February briefly refused to review Moderna’s flu vaccine, citing trial inadequacies, but reversed course a few days later. A verdict is expected by Aug. 5.
June 19, 2026
·
2 min read
·
Tristan Manalac
mRNA
ASCO: Moderna’s mRNA-based melanoma vaccine shows ‘encouraging’ 5-year survival
When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in a mid-stage trial of advanced melanoma—a result analysts said could help “instill confidence” in the regimen.
June 2, 2026
·
2 min read
·
Tristan Manalac
1 of 1,342
Next
